Endometriosis, inflammation, and GLP-1 drugs: Promise, placebo, or a path forward?
Over the past year, a growing number of my patients with endometriosis have reported something unexpected: fewer inflammatory flares, less bloating, and, in some cases, meaningful pain relief after starting GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) for metabolic indications.
These observations are anecdotal and highly...











